Search Videos by Topic or Participant
Browse by Series:

Conclusion: Optimal Side Effect Management in CRC

Panelists: Johanna Bendell, MD, Sarah Cannon; Axel Grothey, MD, Mayo Clinic; Claus-Henning Köhne, MD, PhD, Klinikum Oldenburg; John L. Marshall, MD, Ge
Published: Monday, Jun 17, 2013
For High-Definition, Click
In closing, the panel explores the management of side effects experienced by patients during the treatment colorectal cancer. To address this topic, moderator, John L. Marshall, MD, asks each panelist to provide their unique perspective on the optimal management of a variety of adverse events.

For patients with hand-food syndrome, Johanna Bendell, MD, recommends the application of urea-based creams. Additionally, she advises patients to wear gloves and socks to bed as a means to further alleviate this side effect. In colorectal cancer, hand-foot syndrome is traditionally associated with capecitabine but is now also common with regorafenib.

In the palliative setting, the goal of treatment is to delay tumor progression. As such, Axel Grothey, MD, recommends stopping oxaliplatin after eight cycles, to reduce neuropathy. Additionally, he notes, a non-bolus 5-FU delivery route lessens adverse events. For patients in the palliative setting, Grothey recommends administering modified FOLFOX-7 with 85 mg oxaliplatin for eight cycles. In general, this approach does not cause alopecia and the main side effects include diarrhea and fatigue, Grothey suggests.

In general, steps should be taken to minimize the risk for myelosuppression that accompanies treatment. To accomplish this, Heinz-Josef Lenz, MD, believes dose modifications and administration schedule changes should be performed, rather than utilizing growth factors.

To address asthenia, physicians must first ascertain whether it is a result of treatment or the disease, Claus-Henning Kohne, MD, PhD, suggests. In many cases, a dose reduction can reduce fatigue, rather than completely omitting the treatment.


Slider Left
Slider Right
For High-Definition, Click
In closing, the panel explores the management of side effects experienced by patients during the treatment colorectal cancer. To address this topic, moderator, John L. Marshall, MD, asks each panelist to provide their unique perspective on the optimal management of a variety of adverse events.

For patients with hand-food syndrome, Johanna Bendell, MD, recommends the application of urea-based creams. Additionally, she advises patients to wear gloves and socks to bed as a means to further alleviate this side effect. In colorectal cancer, hand-foot syndrome is traditionally associated with capecitabine but is now also common with regorafenib.

In the palliative setting, the goal of treatment is to delay tumor progression. As such, Axel Grothey, MD, recommends stopping oxaliplatin after eight cycles, to reduce neuropathy. Additionally, he notes, a non-bolus 5-FU delivery route lessens adverse events. For patients in the palliative setting, Grothey recommends administering modified FOLFOX-7 with 85 mg oxaliplatin for eight cycles. In general, this approach does not cause alopecia and the main side effects include diarrhea and fatigue, Grothey suggests.

In general, steps should be taken to minimize the risk for myelosuppression that accompanies treatment. To accomplish this, Heinz-Josef Lenz, MD, believes dose modifications and administration schedule changes should be performed, rather than utilizing growth factors.

To address asthenia, physicians must first ascertain whether it is a result of treatment or the disease, Claus-Henning Kohne, MD, PhD, suggests. In many cases, a dose reduction can reduce fatigue, rather than completely omitting the treatment.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x